Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

Zobrazit celou dokumentaci

D-039

Supelco

N-Desethylamodiaquine dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C18H18ClN3O·2HCl
Číslo CAS:
79049-30-2
Molekulová hmotnost:
400.73
EC Number:
200-659-6
MDL number:
MFCD08063715
UNSPSC Code:
41116107
PubChem Substance ID:
329798602
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

ClC1=CC=C(C(NC2=CC=C(O)C(CNCC)=C2)=CC=N3)C3=C1.Cl.Cl

InChI

1S/C18H18ClN3O.2ClH/c1-2-20-11-12-9-14(4-6-18(12)23)22-16-7-8-21-17-10-13(19)3-5-15(16)17;;/h3-10,20,23H,2,11H2,1H3,(H,21,22);2*1H

InChI key

BCYBRFGUODDEGH-UHFFFAOYSA-N

General description

N-Desethylamodiaquine is an active primary blood metabolite of the antimalarial drug amodiaquine. This certified solution standard is applicable for use in clinical toxicology by LC-MS/MS or GC/MS. Amodiaquine, sold under trade names Camoquin and Flavoquine, is used as an anti-inflammatory agent and as a treatment for malaria.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Seznamy omezení vyplývajících z předpisů

Seznamy omezení vyplývajících z předpisů jsou poskytovány zejména pro chemické produkty. Pro jiné než chemické produkty lze poskytovat pouze omezené informace. Žádný záznam znamená, že v seznamech není obsažena žádná ze součástí. Povinností uživatele je zajistit bezpečné a zákonné použití produktu.

EU REACH Annex XVII (Restriction List)

CAS No.

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 6

1 of 6

1′-Hydroxymidazolam

Sigma-Aldrich

UC430

1′-Hydroxymidazolam

4-Hydroxymephenytoin ≥98% (HPLC)

Sigma-Aldrich

H146

4-Hydroxymephenytoin

Dextrorphan tartrate powder

Sigma-Aldrich

D127

Dextrorphan tartrate

6β-Hydroxytestosterone solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-059

6β-Hydroxytestosterone solution

4′-Hydroxydiclofenac VETRANAL®, analytical standard

Supelco

32412

4′-Hydroxydiclofenac

Furafylline ≥98% (HPLC)

Sigma-Aldrich

F124

Furafylline

V Sinou et al.
European journal of drug metabolism and pharmacokinetics, 34(3-4), 133-142 (2010-02-20)
A new fixed-dose combination of artesunate (AS) plus amodiaquine (AQ) (TRIMALACT) was recently developed for the treatment of uncomplicated falciparum malaria. The originality of this combination lies in its galenic formulation which consists of a three-layer tablet with two layers
Sophie Sarrassat et al.
Acta tropica, 110(1), 1-6 (2008-12-06)
The deployment of Artemisinin-based Combination Therapy for treating uncomplicated malaria poses problems in the patient compliance to these new treatments. The aim of our study was to investigate the relationship between compliance to 3 days treatment with Artesunate plus Amodiaquine
Anupkumar R Anvikar et al.
The Indian journal of medical research, 135(4), 494-499 (2012-06-06)
In vitro assays are an important tool to assess baseline sensitivity and monitor the drug response of Plasmodium falciparum over time and place and, therefore, can provide background information for the development and evaluation of drug policies. This study was
Adriana Pabón et al.
Experimental parasitology, 127(1), 222-227 (2010-08-26)
The effect of 16 alpha-acetoxy-26-hydroxycholest-4-ene-3,22-dione (SN-1) isolated from Solanum nudum Dunal (a Solanaceae traditionally used for treating fever in Colombia) on Plasmodium falciparum erythrocyte stages and its in vitro antiplasmodial activity when combined with the following conventional drugs was studied:
George O Adjei et al.
Malaria journal, 11, 420-420 (2012-12-19)
Several anti-malarial drugs are associated with adverse cardiovascular effects. These effects may be exacerbated when different anti-malarials are used in combination. There has been no report yet on the potential cardiac effects of the combination artesunate-amodiaquine. Electrocardiographic (ECG) intervals in
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.